PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Petros Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -83.3%
Financial strength
- Current ratio
- 1.25
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 122.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.19
- Dividend yield
- –